Pfizer TLR-9 Adjuvant With Prevnar In HIV Patients Hints At Post-Wyeth Vaccine Opportunities
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish academic trial has been looking at how Pfizer/Coley adjuvant can enhance effect of standard Wyeth Prevnar formulation.
You may also be interested in...
FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Narrows Population
The firm is hoping to gain licensure for chronic kidney disease patients first, and eventually to expand the indication to the broader hepatitis B vaccination population.
A Goliath Grows: Pfizer Buys Wyeth For $68 Billion
Merger propels Pfizer ahead in biotechnology and paves the way for the drug giant to navigate the loss of Lipitor in 2011.
Merck’s Heplisav Gets FDA Clinical Hold
Phase III subject diagnosed with Wegener’s granulomatosis, a rare blood vessel inflammation.